RMD

Business profile & competitive position

ResMed Inc. (RMD) sits in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. It is a global developer and marketer of digital-health and cloud-connected medical devices targeting sleep and breathing health. Its hardware lineup includes CPAP, APAP, bilevel and ventilation devices, masks, diagnostics products, dental devices and connected-care software. Beyond devices, the company sells cloud-based Residential Care Software to home medical equipment providers, home-health agencies, hospice operators, skilled-nursing facilities and senior-living communities, and it distributes products in more than 140 countries through subsidiaries and independent distributors.

ResMed reports through two segments: Sleep and Breathing Health, and Residential Care Software. In fiscal 2026, devices produced roughly 51% of net revenue, masks/diagnostics/accessories contributed about 37%, and software represented the remaining 12%. Scale signals show the company employing approximately 11,370 people, with more than 35 million cloud-connected devices on its AirView remote-monitoring platform and over 12 million patients registered on its myAir patient-engagement app.

The numbers give the competitive picture teeth. A 26.9% net margin and 23.9% return on equity are both at the high end of what durable medical-device franchises typically deliver, suggesting meaningful pricing power, recurring mask/accessories revenue and efficient use of shareholder capital. Its beta of 0.75 is below the market average, implying the stock has historically traded with less volatility than the broader equity market, consistent with a defensive, non-discretionary healthcare profile.

Financial posture

At a market capitalization of $33.6 billion and a price-to-earnings ratio of 22.2, ResMed carries a valuation that is neither deep-value nor aggressively stretched on what the company earns today. The stock was recently at $231.46, with the 50-day exponential moving average at $213.37 and an RSI of 61.7, leaving it closer to short-term overbought territory but not historically extreme.

The profitability framework is the stronger part of the balance sheet narrative. The 26.9% net margin and 23.9% ROE both stand out, and the 0.75 beta reinforces the defensive characteristic of a business tied to diagnosed sleep-disordered breathing and chronic respiratory care. The data block does not provide a specific debt figure, so a leverage assessment is not possible from the supplied numbers alone. Still, the combination of double-digit profitability and a below-market beta points to a company with cash-flow-generative assets rather than a speculative growth story.

Strategic priorities & outlook

ResMed’s most recent 10-K frames a strategy built around deepening the core sleep-apnea franchise while moving care closer to the home. Four priorities show up repeatedly:

• Differentiate the core sleep portfolio by integrating artificial intelligence and machine learning, simplifying patient care pathways, and expanding home diagnostics such as NightOwl and the VirtuOx independent diagnostic testing facility acquisition.
• Accelerate market growth through awareness and education aimed at patients, physicians, and special-interest groups for sleep apnea, COPD, and related comorbidities.
• Expand into adjacent conditions including COPD, neuromuscular disease and restless legs syndrome, the last supported by the Noctrix acquisition.
• Build an integrated digital-health ecosystem delivered at home, leaning on AirView remote monitoring and the myAir patient engagement platform.

Operationally, the company is also trying to focus the portfolio. In June 2026 it agreed to sell its MatrixCare business for $490 million in cash, a deal expected to close in the first quarter of fiscal 2027. Management’s message is clear: sharpen attention on core sleep, breathing and connected home-based healthcare rather than software-as-a-service assets that sit further from the device ecosystem.

Macro & geopolitical exposure

Because ResMed is classified under Healthcare / Medical - Instruments & Supplies, the dominant macro exposures are regulatory, reimbursement-oriented and global rather than cyclical. Medical devices sold into the U.S. face Food and Drug Administration oversight, and changes in de novo or 510(k) pathways can affect launch timelines. Abroad, each of the 140-plus markets has its own device-registration and quality-system requirements.

Reimbursement is the other major variable. A large share of sleep and respiratory therapy is paid for by Medicare, Medicaid and private insurers in the U.S., and national health services overseas. Competitive-bidding rounds, fee-schedule cuts or oxygen/CPAP reimbursement changes can compress realized prices faster than volume growth compensates. Tariffs or trade restrictions on Chinese-sourced components, motors, resins or semiconductors also matter for margins, as does foreign-currency translation given the company’s broad international footprint. Finally, supply-chain disruptions for specialized electronics and resins have affected the medical-device industry broadly, and ResMed is exposed to those same input markets.

Recent developments

The most recent headlines around the ticker have been a mix of corporate-governance updates, institutional buying, dividend coverage and one article that uses “RMD” in its required-minimum-distribution sense rather than as the ResMed ticker:

• [2026-08-20] “The IRS Makes You Sell Whether the Market Is Up or Down. These 3 ETFs Fund the RMD Without Touching a Share” (247wallst.com) — This is an ETF/retirement-planning piece using “RMD” as the required-minimum-distribution acronym, not a ResMed-specific story.
• [2026-08-17] “Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor” (globenewswire.com).
• [2026-08-16] “87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co” (defenseworld.net).
• [2026-08-14] “Dividend Champion, Contender, And Challenger Highlights: Week August 16” (seekingalpha.com).

None of these items materially changes the operating narrative, though the board transition is a governance data point investors typically monitor in a mature medical-technology holding.

Earnings behavior & post-earnings drift

ResMed has delivered earnings beats in six of the last eight reported quarters, an 86% beat rate, with an average surprise of 2.6%. The average five-day price move after those reports was 0.24%, classified as flat. That flat average is worth unpacking, because it hides some meaningful day-one pressure.

Across the four most recent quarters, ResMed beat the consensus every time yet the next-day stock reaction was negative in three of the four:

• 2026-08-06: actual EPS $2.95 vs. estimate $2.89 (+2.1% surprise) — the stock fell 5.06% the next day and rose 1.57% over the following five days.
• 2026-04-30: actual EPS $2.86 vs. estimate $2.80 (+2.1% surprise) — the stock fell 4.11% the next day and declined 3.24% over the following five days.
• 2026-01-29: actual EPS $2.81 vs. estimate $2.74 (+2.6% surprise) — the stock rose 0.27% the next day and added 3.66% over the following five days.
• 2025-10-30: actual EPS $2.55 vs. estimate $2.51 (+1.6% surprise) — the stock fell 2.13% the next day and slid 1.03% over the following five days.

The pattern suggests that, while ResMed is consistently beating the official number, the market’s real expectation may already be embedded at or above the printed consensus, and guidance often matters more than the beat itself. The next report is scheduled for 2026-10-29 after the close, with the current consensus EPS estimate at $2.69.

For a deeper dive into how sell-side analysts, quant signals and institutional holders are evaluating ResMed heading into the October 2026 report, review the full institutional verdict on the platform.